MedPath

The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis

Not Applicable
Conditions
Psoriasis
Interventions
Device: NB-UVB
Registration Number
NCT03526705
Lead Sponsor
Cairo University
Brief Summary

Psoriasis is an immune-mediated skin disease that affects 1-2 % of the population. Several cytokines have been found to be involved in the complex pathogenesis of this disease. Il- 36 is one of the cytokines sharing in psoriasis pathogenesis, as its levels are elevated in psoriatic plaques. Cathepsin G is known to activate Il- 36 and promote inflammation in psoriasis.NB-UVB is one of the important treatment modalities for psoriasis.

The aim of this study is to detect the effect of NB-UVB on the lesional levels of IL-36 in psoriasis.

Detailed Description

25 psoriasis patients will receive 26 sessions of phototherapy (NB-UVB). Patients will receive 3 sessions per week. Tissue levels of IL-36 and Cathepsin G will be assessed in skin lesions before starting treatment and after completing the 26 sessions.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
25
Inclusion Criteria
  • Patients with psoriasis vulgaris of both sexes
  • Age between 18 and 60 years old.
Read More
Exclusion Criteria
  • Pregnant females
  • Patients receiving systemic treatment or topical treatment for psoriasis within the past two months.
  • Patients having other dermatological diseases.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
nb-uvbNB-UVBpsoriasis patients will receive 26 sessions of nb-uvb phototherapy
Primary Outcome Measures
NameTimeMethod
changes in Il-36 levels in 25 psoriasis patients after 26 sessions of NB-UVB6 months

primary

Secondary Outcome Measures
NameTimeMethod
changes in cathepsin G levels in 25 psoriasis patients after 26 sessions of NB-UVB psoriasis6 months

secondary

© Copyright 2025. All Rights Reserved by MedPath